PreveCeutical Medical Inc. (
CSE: C.PREV,
Forum) said Monday its subsidiary has entered into an option agreement with Uniquest Pty Ltd. to conduct a research program that will focus on the development of Smart-siRNAs for the treatment of diabetes and obesity.
Uniquest is the main commercialization company for the University of Queensland.
More information can be found
here.
PreveCeutical was in the news recently when the
company said it had signed a research and development agreement with UniQuest Pty Ltd. The agreement covers the extraction, formulation and Ex Vivo Evaluation of Cannabinoids for nose to brain delivery via Sol-Gels.
“Working with UniQuest and the University of Queensland on this research program provides PMI with unique opportunities towards developing products that promote good health and wellness,’’ said PMI Chairman and CEO Stephen Van Deventer.
FULL DISCLOSURE: PreveCeutical Medical Inc. is a paid client of Stockhouse Publishing.